These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 26582863)

  • 1. Hazards of perioperative β-blockers are likely to be dose related.
    Dimmitt SB; Stampfer HG; Warren JB; Paech MJ
    Br J Anaesth; 2015 Dec; 115(6):944. PubMed ID: 26582863
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical practice guidelines on perioperative cardiovascular evaluation: collaborative efforts among the ACC, AHA, and ESC.
    Anderson JL; Antman EM; Harold JG; Jessup M; O'Gara PT; Pinto FJ; Vardas PE; Zamorano JL
    J Am Coll Cardiol; 2014 Dec; 64(22):2371-2. PubMed ID: 25091542
    [No Abstract]   [Full Text] [Related]  

  • 3. ACP Journal Club. Review: Perioperative β-blockade reduces nonfatal MI but increases mortality in noncardiac surgery.
    Brown DL
    Ann Intern Med; 2015 May; 162(10):JC10. PubMed ID: 25984871
    [No Abstract]   [Full Text] [Related]  

  • 4. Perioperative beta blockade in noncardiac surgery: a systematic review for the 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines.
    Wijeysundera DN; Duncan D; Nkonde-Price C; Virani SS; Washam JB; Fleischmann KE; Fleisher LA
    J Am Coll Cardiol; 2014 Dec; 64(22):2406-25. PubMed ID: 25091545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The evolution and future of ACC/AHA clinical practice guidelines: a 30-year journey: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
    Jacobs AK; Anderson JL; Halperin JL
    J Am Coll Cardiol; 2014 Sep; 64(13):1373-84. PubMed ID: 25103073
    [No Abstract]   [Full Text] [Related]  

  • 6. The evolution and future of ACC/AHA clinical practice guidelines: a 30-year journey: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines.
    Jacobs AK; Anderson JL; Halperin JL; ; Anderson JL; Halperin JL; Albert NM; Bozkurt B; Brindis RG; Curtis LH; DeMets D; Fleisher LA; Gidding S; Hochman JS; Kovacs RJ; Ohman EM; Pressler SJ; Sellke FW; Shen WK; Wijeysundera DN
    Circulation; 2014 Sep; 130(14):1208-17. PubMed ID: 25092464
    [No Abstract]   [Full Text] [Related]  

  • 7. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 2: Preparticipation Screening for Cardiovascular Disease in Competitive Athletes: A Scientific Statement From the American Heart Association and American College of Cardiology.
    Maron BJ; Levine BD; Washington RL; Baggish AL; Kovacs RJ; Maron MS;
    Circulation; 2015 Dec; 132(22):e267-72. PubMed ID: 26527714
    [No Abstract]   [Full Text] [Related]  

  • 8. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 4: Congenital Heart Disease: A Scientific Statement From the American Heart Association and American College of Cardiology.
    Van Hare GF; Ackerman MJ; Evangelista JA; Kovacs RJ; Myerburg RJ; Shafer KM; Warnes CA; Washington RL;
    Circulation; 2015 Dec; 132(22):e281-91. PubMed ID: 26621645
    [No Abstract]   [Full Text] [Related]  

  • 9. 2012 ACCF/AHA/HRS focused update of the 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. [corrected].
    Tracy CM; Epstein AE; Darbar D; DiMarco JP; Dunbar SB; Estes NA; Ferguson TB; Hammill SC; Karasik PE; Link MS; Marine JE; Schoenfeld MH; Shanker AJ; Silka MJ; Stevenson LW; Stevenson WG; Varosy PD; Ellenbogen KA; Freedman RA; Gettes LS; Gillinov AM; Gregoratos G; Hayes DL; Page RL; Stevenson LW; Sweeney MO; ; ;
    Circulation; 2012 Oct; 126(14):1784-800. PubMed ID: 22965336
    [No Abstract]   [Full Text] [Related]  

  • 10. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 5: Valvular Heart Disease: A Scientific Statement From the American Heart Association and American College of Cardiology.
    Bonow RO; Nishimura RA; Thompson PD; Udelson JE;
    Circulation; 2015 Dec; 132(22):e292-7. PubMed ID: 26621646
    [No Abstract]   [Full Text] [Related]  

  • 11. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 1: Classification of Sports: Dynamic, Static, and Impact: A Scientific Statement From the American Heart Association and American College of Cardiology.
    Levine BD; Baggish AL; Kovacs RJ; Link MS; Maron MS; Mitchell JH;
    Circulation; 2015 Dec; 132(22):e262-6. PubMed ID: 26621643
    [No Abstract]   [Full Text] [Related]  

  • 12. Management of patients with peripheral artery disease (compilation of 2005 and 2011 ACCF/AHA guideline recommendations): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.
    Anderson JL; Halperin JL; Albert NM; Bozkurt B; Brindis RG; Curtis LH; DeMets D; Guyton RA; Hochman JS; Kovacs RJ; Ohman EM; Pressler SJ; Sellke FW; Shen WK
    Circulation; 2013 Apr; 127(13):1425-43. PubMed ID: 23457117
    [No Abstract]   [Full Text] [Related]  

  • 13. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America.
    Yancy CW; Jessup M; Bozkurt B; Butler J; Casey DE; Colvin MM; Drazner MH; Filippatos GS; Fonarow GC; Givertz MM; Hollenberg SM; Lindenfeld J; Masoudi FA; McBride PE; Peterson PN; Stevenson LW; Westlake C
    J Card Fail; 2017 Aug; 23(8):628-651. PubMed ID: 28461259
    [No Abstract]   [Full Text] [Related]  

  • 14. Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations): a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines.
    ; ; ; ; Wann LS; Curtis AB; Ellenbogen KA; Estes NA; Ezekowitz MD; Jackman WM; January CT; Lowe JE; Page RL; Slotwiner DJ; Stevenson WG; Tracy CM; Fuster V; Rydén LE; Cannom DS; Crijns HJ; Curtis AB; Ellenbogen KA; Halperin JL; Le Heuzey J; Kay GN; Lowe JE; Olsson SB; Prystowsky EN; Tamargo JL; Wann LS
    Circulation; 2013 May; 127(18):1916-26. PubMed ID: 23545139
    [No Abstract]   [Full Text] [Related]  

  • 15. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 6: Hypertension: A Scientific Statement from the American Heart Association and the American College of Cardiology.
    Black HR; Sica D; Ferdinand K; White WB;
    Circulation; 2015 Dec; 132(22):e298-302. PubMed ID: 26621647
    [No Abstract]   [Full Text] [Related]  

  • 16. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 14: Sickle Cell Trait: A Scientific Statement From the American Heart Association and American College of Cardiology.
    Maron BJ; Harris KM; Thompson PD; Eichner ER; Steinberg MH;
    Circulation; 2015 Dec; 132(22):e343-5. PubMed ID: 26527715
    [No Abstract]   [Full Text] [Related]  

  • 17. Eligibility and Disqualification Recommendations for Competitive Athletes with Cardiovascular Abnormalities: Task Force 8: Coronary Artery Disease: A Scientific Statement from the American Heart Association and American College of Cardiology.
    Thompson PD; Myerburg RJ; Levine BD; Udelson JE; Kovacs RJ;
    Circulation; 2015 Dec; 132(22):e310-4. PubMed ID: 26621649
    [No Abstract]   [Full Text] [Related]  

  • 18. ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines.
    Anderson JL; Heidenreich PA; Barnett PG; Creager MA; Fonarow GC; Gibbons RJ; Halperin JL; Hlatky MA; Jacobs AK; Mark DB; Masoudi FA; Peterson ED; Shaw LJ
    J Am Coll Cardiol; 2014 Jun; 63(21):2304-22. PubMed ID: 24681044
    [No Abstract]   [Full Text] [Related]  

  • 19. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 11: Drugs and Performance-Enhancing Substances: A Scientific Statement From the American Heart Association and American College of Cardiology.
    Estes NA; Kovacs RJ; Baggish AL; Myerburg RJ;
    Circulation; 2015 Dec; 132(22):e330-3. PubMed ID: 26621651
    [No Abstract]   [Full Text] [Related]  

  • 20. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 9: Arrhythmias and Conduction Defects: A Scientific Statement From the American Heart Association and American College of Cardiology.
    Zipes DP; Link MS; Ackerman MJ; Kovacs RJ; Myerburg RJ; Estes NA;
    Circulation; 2015 Dec; 132(22):e315-25. PubMed ID: 26621650
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.